237 related articles for article (PubMed ID: 27711199)
1. A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).
Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Inoue A; Atsumi T; Manda N; Kurihara Y; Aoki S;
PLoS One; 2016; 11(10):e0164255. PubMed ID: 27711199
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
Nomoto H; Miyoshi H; Furumoto T; Oba K; Tsutsui H; Miyoshi A; Kondo T; Tsuchida K; Atsumi T; Manda N; Kurihara Y; Aoki S;
PLoS One; 2015; 10(8):e0135854. PubMed ID: 26284918
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial).
Terauchi Y; Yamada Y; Ishida H; Ohsugi M; Kitaoka M; Satoh J; Yabe D; Shihara N; Seino Y
Diabetes Obes Metab; 2017 Aug; 19(8):1188-1192. PubMed ID: 28294488
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
[TBL] [Abstract][Full Text] [Related]
6. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
9. The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Kitao N; Miyoshi H; Furumoto T; Ono K; Nomoto H; Miya A; Yamamoto C; Inoue A; Tsuchida K; Manda N; Kurihara Y; Aoki S; Nakamura A; Atsumi T;
Cardiovasc Diabetol; 2017 Oct; 16(1):125. PubMed ID: 29017497
[TBL] [Abstract][Full Text] [Related]
10. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
13. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
Srivastava S; Saxena GN; Keshwani P; Gupta R
J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea.
Khaloo P; Asadi Komeleh S; Alemi H; Mansournia MA; Mohammadi A; Yadegar A; Afarideh M; Esteghamati S; Nakhjavani M; Esteghamati A
J Endocrinol Invest; 2019 Jul; 42(7):851-857. PubMed ID: 30535871
[TBL] [Abstract][Full Text] [Related]
15. Both glimepiride and high-dose metformin are important for sustained glucose lowering in Japanese type 2 diabetes patients on glimepiride-sitagliptin-metformin therapy: subanalysis of a single-center, open-label, randomized study.
Arai K; Maeda H; Shirabe S; Yamamoto R; Kumakura A; Yamauchi M; Hirao T; Hirao S; Hirao K
Diabetes Technol Ther; 2014 Jul; 16(7):442-6. PubMed ID: 24528246
[TBL] [Abstract][Full Text] [Related]
16. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
17. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study.
Nakamura K; Oe H; Kihara H; Shimada K; Fukuda S; Watanabe K; Takagi T; Yunoki K; Miyoshi T; Hirata K; Yoshikawa J; Ito H
Cardiovasc Diabetol; 2014 Jul; 13():110. PubMed ID: 25074318
[TBL] [Abstract][Full Text] [Related]
18. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
[TBL] [Abstract][Full Text] [Related]
19. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study.
Sakura H; Hashimoto N; Sasamoto K; Ohashi H; Hasumi S; Ujihara N; Kasahara T; Tomonaga O; Nunome H; Honda M; Iwamoto Y;
BMC Endocr Disord; 2016 Dec; 16(1):70. PubMed ID: 27905912
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
